vs

Side-by-side financial comparison of ALEXANDERS INC (ALX) and ARDELYX, INC. (ARDX). Click either name above to swap in a different company.

ARDELYX, INC. is the larger business by last-quarter revenue ($94.5M vs $53.3M, roughly 1.8× ALEXANDERS INC). On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs -4.7%). Over the past eight quarters, ARDELYX, INC.'s revenue compounded faster (13.6% CAGR vs -6.9%).

Alexander's, Inc. is a real estate investment trust that owns 7 properties in New York metropolitan area, including 731 Lexington Avenue, the headquarters of Bloomberg L.P. It is controlled by Vornado Realty Trust. It was founded by George Farkas and Louis Schwadron in 1928.

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

ALX vs ARDX — Head-to-Head

Bigger by revenue
ARDX
ARDX
1.8× larger
ARDX
$94.5M
$53.3M
ALX
Growing faster (revenue YoY)
ARDX
ARDX
+32.2% gap
ARDX
27.5%
-4.7%
ALX
Faster 2-yr revenue CAGR
ARDX
ARDX
Annualised
ARDX
13.6%
-6.9%
ALX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ALX
ALX
ARDX
ARDX
Revenue
$53.3M
$94.5M
Net Profit
$-37.6M
Gross Margin
Operating Margin
Net Margin
-39.8%
Revenue YoY
-4.7%
27.5%
Net Profit YoY
EPS (diluted)
$0.75
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALX
ALX
ARDX
ARDX
Q1 26
$94.5M
Q4 25
$53.3M
$125.2M
Q3 25
$53.4M
$110.3M
Q2 25
$51.6M
$97.7M
Q1 25
$54.9M
$74.1M
Q4 24
$55.9M
$116.1M
Q3 24
$55.7M
$98.2M
Q2 24
$53.4M
$73.2M
Net Profit
ALX
ALX
ARDX
ARDX
Q1 26
$-37.6M
Q4 25
$-407.0K
Q3 25
$6.0M
$-969.0K
Q2 25
$6.1M
$-19.1M
Q1 25
$12.3M
$-41.1M
Q4 24
$4.6M
Q3 24
$6.7M
$-809.0K
Q2 24
$8.4M
$-16.5M
Gross Margin
ALX
ALX
ARDX
ARDX
Q1 26
Q4 25
91.3%
Q3 25
96.4%
Q2 25
87.3%
Q1 25
83.4%
Q4 24
84.3%
Q3 24
84.0%
Q2 24
87.1%
Operating Margin
ALX
ALX
ARDX
ARDX
Q1 26
Q4 25
4.1%
Q3 25
4.2%
Q2 25
-14.7%
Q1 25
-49.0%
Q4 24
7.0%
Q3 24
2.3%
Q2 24
-18.6%
Net Margin
ALX
ALX
ARDX
ARDX
Q1 26
-39.8%
Q4 25
-0.3%
Q3 25
11.2%
-0.9%
Q2 25
11.9%
-19.5%
Q1 25
22.4%
-55.5%
Q4 24
4.0%
Q3 24
12.0%
-0.8%
Q2 24
15.7%
-22.5%
EPS (diluted)
ALX
ALX
ARDX
ARDX
Q1 26
$-0.15
Q4 25
$0.75
$-0.01
Q3 25
$1.16
$0.00
Q2 25
$1.19
$-0.08
Q1 25
$2.40
$-0.17
Q4 24
$2.39
$0.01
Q3 24
$1.30
$0.00
Q2 24
$1.63
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALX
ALX
ARDX
ARDX
Cash + ST InvestmentsLiquidity on hand
$128.2M
$238.1M
Total DebtLower is stronger
$203.5M
Stockholders' EquityBook value
$109.2M
$148.6M
Total Assets
$1.1B
$504.5M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALX
ALX
ARDX
ARDX
Q1 26
$238.1M
Q4 25
$128.2M
$68.0M
Q3 25
$286.1M
$42.7M
Q2 25
$313.0M
$90.0M
Q1 25
$319.9M
$30.8M
Q4 24
$338.5M
$64.9M
Q3 24
$354.8M
$47.4M
Q2 24
$410.9M
$41.9M
Total Debt
ALX
ALX
ARDX
ARDX
Q1 26
$203.5M
Q4 25
$202.8M
Q3 25
$202.1M
Q2 25
$201.4M
Q1 25
$151.3M
Q4 24
$150.9M
Q3 24
$100.7M
Q2 24
$100.2M
Stockholders' Equity
ALX
ALX
ARDX
ARDX
Q1 26
$148.6M
Q4 25
$109.2M
$166.9M
Q3 25
$128.3M
$154.3M
Q2 25
$145.4M
$139.5M
Q1 25
$163.1M
$145.7M
Q4 24
$176.9M
$173.3M
Q3 24
$190.7M
$158.3M
Q2 24
$212.5M
$147.0M
Total Assets
ALX
ALX
ARDX
ARDX
Q1 26
$504.5M
Q4 25
$1.1B
$501.6M
Q3 25
$1.3B
$486.2M
Q2 25
$1.3B
$466.8M
Q1 25
$1.3B
$410.2M
Q4 24
$1.3B
$435.8M
Q3 24
$1.4B
$367.9M
Q2 24
$1.5B
$343.5M
Debt / Equity
ALX
ALX
ARDX
ARDX
Q1 26
1.37×
Q4 25
1.21×
Q3 25
1.31×
Q2 25
1.44×
Q1 25
1.04×
Q4 24
0.87×
Q3 24
0.64×
Q2 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALX
ALX
ARDX
ARDX
Operating Cash FlowLast quarter
$73.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALX
ALX
ARDX
ARDX
Q1 26
Q4 25
$73.4M
$21.0M
Q3 25
$-9.3M
$365.0K
Q2 25
$43.6M
$-25.3M
Q1 25
$15.7M
$-38.5M
Q4 24
$54.1M
$9.8M
Q3 24
$-5.0M
$501.0K
Q2 24
$11.5M
$-19.4M
Free Cash Flow
ALX
ALX
ARDX
ARDX
Q1 26
Q4 25
$20.6M
Q3 25
$209.0K
Q2 25
$-26.0M
Q1 25
$-38.8M
Q4 24
$9.2M
Q3 24
$364.0K
Q2 24
$-19.5M
FCF Margin
ALX
ALX
ARDX
ARDX
Q1 26
Q4 25
16.4%
Q3 25
0.2%
Q2 25
-26.6%
Q1 25
-52.3%
Q4 24
7.9%
Q3 24
0.4%
Q2 24
-26.7%
Capex Intensity
ALX
ALX
ARDX
ARDX
Q1 26
Q4 25
0.3%
Q3 25
0.1%
Q2 25
0.7%
Q1 25
0.4%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.2%
Cash Conversion
ALX
ALX
ARDX
ARDX
Q1 26
Q4 25
Q3 25
-1.55×
Q2 25
7.12×
Q1 25
1.28×
Q4 24
2.11×
Q3 24
-0.75×
Q2 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALX
ALX

Segment breakdown not available.

ARDX
ARDX

IBSRELA$70.1M74%
XPHOZAH$23.3M25%
Non-cash royalty revenue related to the sale of future royalties$695.0K1%
Product supply revenue$354.0K0%

Related Comparisons